Date: Mar 26, 2013 Source: (
click here to go to the source)
With a $150,000 grant from the National Human Genome Research Institute, startup Twistnostics is hoping to demonstrate the potential of its single-molecule array technology to support rapid multiplex molecular diagnostics.
In a pilot project funded by the NHGRI grant, Twistnostics hopes to demonstrate that its so-called Twist-Biosensors can detect three SNPs in the CYP2D6 gene associated with variations in human drug metabolism. The firm intends to then develop the technology to support the creation of 50- to 100-SNP microarrays for pharmacogenomic genotyping and use in other diagnostic areas like infectious disease and early cancer detection.
Alfredo Celedon, Twistnostics' founder, told BioArray News that the company's approach is based on work he did as a graduate student at Johns Hopkins University, where the company is now located in an incubator space.
